• Disease
  • Chronic
  • Chronic Constipation
  • Stefan A Muller‐lissner

    Prominent publications by Stefan A MULLER‐LISSNER

    KOL Index score: 13202

    BACKGROUND: It has been proposed that treatments for irritable bowel syndrome with constipation (IBS-C) should provide rapid symptomatic relief, be intermittent, and effective upon repeated use.

    AIMS: To evaluate the efficacy and safety of tegaserod on IBS symptoms, and its impact on quality of life and health economic measures.

    PATIENTS: Women (> or = 18 years of age) with IBS-C according to the Rome II criteria.

    METHODS: Prospective, double blind, placebo controlled, randomised trial. ...

    Also Ranks for: Irritable Bowel Syndrome |  tegaserod placebo |  ibs symptoms |  quality life |  randomised controlled trial
    KOL Index score: 12530

    AIM: To investigate the efficacy and safety of tegaserod, a novel 5-HT(4) receptor partial agonist, in a randomized, double-blind, placebo-controlled, 12-week treatment, multicentre study.

    METHODS: Eight hundred and eighty-one patients with irritable bowel syndrome, characterized by abdominal pain, bloating and constipation, received tegaserod, 2 mg b.d. or 6 mg b.d., or placebo for 12 weeks.

    RESULTS: Tegaserod, 2 mg b.d. and 6 mg b.d., showed a statistically significant relief of ...

    Also Ranks for: Abdominal Pain |  tegaserod placebo |  ht4 receptor |  bowel syndrome |  bloating constipation
    KOL Index score: 12392

    OBJECTIVES: Chronic constipation is a common, persistent disorder with limited effective treatment options. This study investigated the efficacy, safety, and tolerability of tegaserod in the treatment of chronic constipation.

    METHODS: After a 2-wk baseline period, patients were randomized to double-blind treatment of 12 wk with tegaserod (2 or 6 mg b.i.d.) or placebo. Response during weeks 1-4 (primary variable) was defined as an increase in complete spontaneous bowel movement (CSBM)/wk. ...

    Also Ranks for: Chronic Constipation |  tegaserod placebo |  6 bid |  bowel habits |  response weeks
    KOL Index score: 10897

    OBJECTIVE: Opioid therapy is frequently associated with treatment-limiting constipation. Naloxone is an opioid antagonist with low oral systemic bioavailability. This Phase III clinical trial assessed the safety and efficacy of an oral fixed-ratio combination of oxycodone prolonged-release (PR) and naloxone PR compared with oxycodone PR in relieving opioid-induced constipation.

    STUDY DESIGN: This double-blind, multicenter trial was conducted in specialist and primary care centers in four ...

    Also Ranks for: Oxycodone Naloxone |  induced constipation |  opioid therapy |  pain intensity |  ratio combination
    KOL Index score: 10224

    BACKGROUND: The nonselective 5-HT(4) receptor agonists, cisapride and tegaserod have been associated with cardiovascular adverse events (AEs).

    AIM: To perform a systematic review of the safety profile, particularly cardiovascular, of 5-HT(4) agonists developed for gastrointestinal disorders, and a nonsystematic summary of their pharmacology and clinical efficacy.

    METHODS: Articles reporting data on cisapride, clebopride, prucalopride, mosapride, renzapride, tegaserod, TD-5108 ...

    Also Ranks for: Gastrointestinal Disorders |  ht4 agonists |  cardiovascular safety |  velusetrag naronapride |  clinical data
    KOL Index score: 9925

    BACKGROUND: Constipation affects up to 50% of the elderly; this study evaluates the efficacy, safety, and tolerability of the selective 5-HT(4) agonist prucalopride in chronically constipated elderly patients.

    METHODS: Three hundred chronic constipation patients aged >or=65 years were randomized to prucalopride (1, 2, or 4 mg once daily) or placebo for 4 weeks. The primary endpoint was the percentage of patients with >or=3 spontaneous complete bowel movements (SCBM) per week. Secondary ...

    Also Ranks for: Chronic Constipation |  elderly patients |  prucalopride placebo |  safety tolerability |  male quality
    KOL Index score: 9742

    Predictors of duodenal ulcer healing and relapse were examined in a population known to have a high healing incidence. Two double-blind prospective studies were performed in 134 patients over 4 wk and in 66 patients over 1 yr, respectively. Short-term treatment consisted either of cimetidine 1 g/day, pirenzepine 75 mg/day, or placebo. In a multiple stepwise linear regression analysis the following factors proved to increase healing incidence in decreasing order of importance: female sex, ...

    Also Ranks for: Ulcer Healing |  bedtime placebo |  cimetidine treatment |  factors smoking |  female sex
    KOL Index score: 9431

    Long-term esophageal pH-metry has become the preferred test to quantify acid gastroesophageal reflux, but its accuracy in separating physiologic from pathological reflux is not well defined. To establish optimal thresholds of 24-h pH-metry, we studied 45 patients with clinically proven gastroesophageal reflux disease and 42 healthy volunteers. Twenty-four-hour esophageal pH was measured while the subject was ambulatory, using a combined glass electrode connected to a portable recorder. ...

    Also Ranks for: Optimal Thresholds |  time esophageal |  reflux disease |  sensitivity specificity |  physiologic predictive
    KOL Index score: 9264

    The Rome diagnostic criteria for the functional bowel disorders and functional abdominal pain are used widely in research and practice. A committee consensus approach, including criticism from multinational expert reviewers, was used to revise the diagnostic criteria and update diagnosis and treatment recommendations, based on research results. The terminology was clarified and the diagnostic criteria and management recommendations were revised. A functional bowel disorder (FBD) is ...

    Also Ranks for: Functional Abdominal Pain |  bowel disorders |  12 weeks |  diagnostic testing |  daily activities
    KOL Index score: 9120

    There are many strongly held beliefs about constipation that are not evidence based. The purpose of this review is to address these beliefs concerning various aspects of constipation. There is no evidence to support the theory that diseases may arise via "autointoxication," whereby poisonous substances from stools within the colon are absorbed. Dolichocolon, defined as an elongated colon, should not be seen as a cause of constipation. The role of sex hormones altering gut function during ...

    Also Ranks for: Chronic Constipation |  sex hormones |  elongated colon |  dietary fiber intake |  decreased physical activity
    KOL Index score: 9062

    Opioid-induced constipation (OIC) is a severe, persisting side-effect of opioid therapy. The Bowel Function Index (BFI(a), numerical analogue scale 0 - 100), calculated as the mean of three variables (ease of defaecation, feeling of incomplete bowel evacuation, and personal judgement of constipation) was developed to evaluate bowel function in opioid-treated patients with pain. This clinician-administered tool allows easy measurement of OIC from the patient's perspective. The purpose of ...

    Also Ranks for: Bowel Function |  pain patients |  reference range |  opioid chronic |  bfi scores
    KOL Index score: 8816

    OBJECTIVE: The Bowel Function Index (BFI) is a clinician-administered, patient-reported, 3-item questionnaire to evaluate opioid-induced constipation in cancer and non-cancer chronic pain patients. The objective of the present analysis was to evaluate the psychometric characteristics of the BFI using data from clinical studies of oral prolonged release (PR) oxycodone/naloxone.

    METHODS: OXN2401 was a multicenter, controlled, randomized, double-blind, parallel-group study including oral PR ...

    Also Ranks for: Bowel Function |  induced constipation |  oral oxycodone |  illness surveys |  clinically meaningful
    KOL Index score: 8637

    OBJECTIVE: To assess the long-term safety and tolerability of tegaserod in patients with chronic constipation (CC).

    METHODS: This 13-month, uncontrolled extension study enrolled CC patients who completed a 12-wk randomized, double-blind, placebo-controlled core study. Patients receiving tegaserod 6 or 2 mg b.i.d. during the core study continued on the same dose; those receiving placebo were switched to tegaserod 6 mg b.i.d (placebo-to-tegaserod). Safety and tolerability were assessed by ...

    Also Ranks for: Chronic Constipation |  patients tegaserod |  abdominal pain |  laboratory parameters |  term treatment
    KOL Index score: 8399

    BACKGROUND: In the absence of highly specific symptoms and without esophageal erosions, long-term pH monitoring is necessary for diagnosing gastroesophageal reflux disease. This method, however, is not generally available.

    OBJECTIVE: To determine whether gastroesophageal reflux disease can be diagnosed empirically by acid suppression in patients with normal results of endoscopy.

    METHODS: We studied 33 consecutive outpatients with pathologic findings on pH monitoring who had symptoms ...

    Also Ranks for: Gastroesophageal Reflux Disease |  severity symptoms |  omeprazole 40 |  patients normal |  acid suppression


    Stefan A MULLER‐LISSNER: Influence Statistics

    Sample of concepts for which Stefan A MULLER‐LISSNER is among the top experts in the world.
    Concept World rank
    mmol omeprazole #1
    67 mumol stomach #1
    atropine reflux #1
    entered retreatment #1
    disorder defecation #1
    laxatives efficacy #1
    healthy controls anismus #1
    123 mumol findings #1
    behandeln differential humans #1
    laxative intake #1
    inconclusive symptomatology #1
    constipated patients psc #1
    retreatment tegaserod retreatment #1
    bowel function oic #1
    beverages constipation #1
    oesophageal erosions #1
    trinkmenge körperliche aktivität #1
    increased prevalence constipation #1
    coffee 1424 #1
    constipation abdominal complaints #1
    gastric bile #1
    60 discriminant analysis #1
    woher #1
    received tegaserod #1
    oic severe persisting #1
    study oxn3401 #1
    oxn3401 data #1
    classified pathological #1
    proctosurgery #1
    salinic laxatives #1
    constipation current #1
    051±017 #1
    longterm esophageal metry #1
    initial treatment tegaserod #1
    proctologic exam #1
    constipated chronic #1
    sennoside treatment #1
    evaluating constipation #1
    441 114 mumol #1
    esophagogastric junction gord #1
    021 76 mmol #1
    psc anorectal #1
    esophageal upright position #1
    kommt lässt #1

    Key People For Chronic Constipation

    Top KOLs in the world
    Camilleri Camilleri
    irritable bowel syndrome colonic transit gastric emptying
    Michael A Kamm
    faecal incontinence ulcerative colitis inflammatory bowel disease
    Nicholas Joseph Talley
    functional dyspepsia irritable bowel syndrome emergency action
    Alan R Zinsmeister
    irritable bowel syndrome olmsted county colonic transit
    William D Chey
    irritable bowel syndrome helicobacter pylori chronic constipation
    Arnold M Wald
    fecal incontinence chronic constipation multiple sclerosis

    Stefan A MULLER‐LISSNER:Expert Impact

    Concepts for whichStefan A MULLER‐LISSNERhas direct influence:Chronic constipation,  Irritable bowel syndrome,  Duodenogastric reflux,  Gastric emptying,  Bile salt reflux,  Bowel syndrome,  Intermittent treatment,  Irritable bowel.

    Stefan A MULLER‐LISSNER:KOL impact

    Concepts related to the work of other authors for whichfor which Stefan A MULLER‐LISSNER has influence:Irritable bowel syndrome,  Chronic constipation,  Gastroesophageal reflux,  Functional dyspepsia,  Ibs patients,  Abdominal pain,  Quality life.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Department of Internal Medicine, Park-Klinik Weissensee, Berlin, Germany | Innere Medizin, Park-Klinik Weissensee, Berlin, Germany. | Park-Klinik Weissensee, 13086 Berlin, Germany | Park-Klinik Weissensee, Schönstrasse 80, D-13086, Berlin, Deutschlan